BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 6681588)

  • 1. A new life-long hemorrhagic disorder due to excess plasminogen activator.
    Booth NA; Bennett B; Wijngaards G; Grieve JH
    Blood; 1983 Feb; 61(2):267-75. PubMed ID: 6681588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A familial hemorrhagic diathesis in a Dutch family: an inherited deficiency of alpha 2-antiplasmin.
    Kluft C; Vellenga E; Brommer EJ; Wijngaards G
    Blood; 1982 Jun; 59(6):1169-80. PubMed ID: 6177359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alpha2-antiplasmin and its deficiency: fibrinolysis out of balance.
    Carpenter SL; Mathew P
    Haemophilia; 2008 Nov; 14(6):1250-4. PubMed ID: 19141165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inherited disorders of the fibrinolytic pathway.
    Jain S; Acharya SS
    Transfus Apher Sci; 2019 Oct; 58(5):572-577. PubMed ID: 31427261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. alpha 2-Antiplasmin Enschede: dysfunctional alpha 2-antiplasmin molecule associated with an autosomal recessive hemorrhagic disorder.
    Kluft C; Nieuwenhuis HK; Rijken DC; Groeneveld E; Wijngaards G; van Berkel W; Dooijewaard G; Sixma JJ
    J Clin Invest; 1987 Nov; 80(5):1391-400. PubMed ID: 2445779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The haemostatic balance in groups of thrombosis-prone patients. With particular reference to fibrinolysis in patients with myocardial infarction.
    Gram J
    Dan Med Bull; 1990 Jun; 37(3):210-34. PubMed ID: 2192835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methods for studying fibrinolytic pathway components in human plasma.
    Wohl RC; Sinio L; Robbins KC
    Thromb Res; 1982 Sep; 27(5):523-35. PubMed ID: 6217585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Excessive fibrinolysis in suspected amyloidosis: demonstration of plasmin-alpha 2-plasmin inhibitor complex and von Willebrand factor fragment in plasma.
    Takahashi H; Koike T; Yoshida N; Kitahara O; Hanano M; Shibata A; Aoki N
    Am J Hematol; 1986 Oct; 23(2):153-66. PubMed ID: 2944378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The fibrinolytic system in man.
    Collen D; Lijnen HR
    Crit Rev Oncol Hematol; 1986; 4(3):249-301. PubMed ID: 2420482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathologic fibrinolysis as a cause of clinical bleeding.
    Stump DC; Taylor FB; Nesheim ME; Giles AR; Dzik WH; Bovill EG
    Semin Thromb Hemost; 1990 Jul; 16(3):260-73. PubMed ID: 2237447
    [No Abstract]   [Full Text] [Related]  

  • 11. Fibrinolysis in health and disease: severe abnormalities in systemic lupus erythematosus.
    Glas-Greenwalt P; Kant KS; Allen C; Pollak VE
    J Lab Clin Med; 1984 Dec; 104(6):962-76. PubMed ID: 6239000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physiologic regulation and pathologic disorders of fibrinolysis.
    Francis CW; Marder VJ
    Hum Pathol; 1987 Mar; 18(3):263-74. PubMed ID: 3546075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of cross-linking of alpha 2-plasmin inhibitor to fibrin in inhibition of fibrinolysis and in hemostasis.
    Sakata Y; Aoki N
    J Clin Invest; 1982 Mar; 69(3):536-42. PubMed ID: 7199538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Fibrinolytic system in patients with myocardial infarction and other coronary disease risk factors].
    Moreno JA; Gálvez MM; Cornudella R; Angós JA; Romero MS; Gutiérrez M
    Sangre (Barc); 1994 Apr; 39(2):111-6. PubMed ID: 8059288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibrinolysis and acquired alpha-2 plasmin inhibitor deficiency in amyloidosis.
    Meyer K; Williams EC
    Am J Med; 1985 Sep; 79(3):394-6. PubMed ID: 4036990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
    Matsuo O; Rijken DC; Collen D
    Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasmin-alpha 2-antiplasmin complexes in bleeding disorders characterized by primary or secondary fibrinolysis.
    Booth NA; Bennett B
    Br J Haematol; 1984 Apr; 56(4):545-56. PubMed ID: 6201189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inherited fibrinolytic disorder due to an enhanced plasminogen activator level.
    Aznar J; Estellés A; Vila V; Regañón E; España F; Villa P
    Thromb Haemost; 1984 Oct; 52(2):196-200. PubMed ID: 6543037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue-type plasminogen activator, type 1 plasminogen activator inhibitor and their complex in plasma with disseminated intravascular coagulation.
    Fukao H; Ueshima S; Okada K; Yamamoto K; Matsuo T; Matsuo O
    Thromb Res; 1992 Oct; 68(1):57-65. PubMed ID: 1280377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The behavior of alpha2-plasmin inhibitor in fibrinolytic states.
    Aoki N; Moroi M; Matsuda M; Tachiya K
    J Clin Invest; 1977 Aug; 60(2):361-9. PubMed ID: 68962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.